Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2018, February 2018
|
Series: | CADTH common drug review clinical review report
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults |
---|---|
Physical Description: | 1 PDF file (112 pages) illustrations |